|

NXP900 Clinical Trials

2 actively recruiting trials across 2 locations

Phoenix, Arizona1 trial

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Mayo Clinic

Phase 1

Boston, Massachusetts1 trial

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Massachusetts General Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.